Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of DSP-0390 in Patients With Recurrent High-Grade Glioma

NCT05023551 is registered in ClinicalTrials.gov with Sumitomo Pharma America, Inc. as lead sponsor.

NCT NCT05023551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05023551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
Lead sponsor
Sumitomo Pharma America, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 8, 2021
Completion date
October 31, 2027
Enrollment
39 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme, high grade glioma